Clinical & translational oncology

• 

  Año 2026, Vol. 28, Número 9

  • EDITORIAL

    • Existing challenges in the management of cholangiocarcinoma in Spain

      Andrés Jesús Muñoz Martín, Ángela Lamarca Lete, Jesus M. Banales, Mar Iglesias, Teresa Macarulla Mercadé

      págs. 3589-3593

      

  • REVIEW ARTICLE

    • Reprogramming resistance in advanced lung cancer: epigenetic modulation to restore therapeutic vulnerability

      Fang He, Mostafa Hossam El Din Moawad, Mohamed A. Alsaied, Hamza A. Abdul Hafez, Hani A. Alhadrami, Ady Ahmed Azhari, Bashar Abdulhakem Abu Nawas

      • Resumen

      págs. 3594-3614

      

    • Exploring tyrosine kinase inhibitors for HER2-positive breast cancer: comprehensive review on a complete pharmacology-molecular mechanisms, safety profiles, and insights from preclinical and clinical studies

      Meghraj V. Suryawanshi, Rukaiya T. Girase, Vishal S. Bagul, Pranjal P. Gujarathi

      • Resumen

      págs. 3615-3631

      

    • Innovative immunotherapeutic strategies for thyroid cancer: challenges and opportunities

      Jinpeng Cui, Huali Fang, Changhua Qu

      • Resumen

      págs. 3632-3650

      

    • Progress in management of advanced clear-cell renal cell carcinoma

      Letong Zhang, Jingwen Wang, Junming Hu, Jiaxi Yao

      • Resumen

      págs. 3651-3667

      

    • Circulating tumor DNA-based detection of molecular residual disease in isocitrate dehydrogenase-mutant cholangiocarcinoma for biomarker-guided therapy

      Alexei Valerievich Yumashev, Boymuradov Shuxrat, Kasimov Khayotbek, Umid Kodirov, Aziza Elmurodova, Abdualimov Rufat, Nilufar Urinova, Iroda Abduraxmonova

      • Resumen

      págs. 3668-3681

      

    • Engineering the next generation of cellular therapies for solid tumors: multi-specific armored CARs and TME reprogramming strategies

      Ling Mao, Lingfang Ding, Yunxia Ding

      • Resumen

      págs. 3682-3696

      

    • Epigenetic insights and innovations for overcoming barriers in CAR-T cell therapy for cancer

      Viktoria B. Poluektova, Svetlana N. Zuevskaya, Yarmatov Suvon, Sharipova Gulnihol, Rustam Turakulov, Feruza Umirkulova

      • Resumen

      págs. 3697-3707

      

    • The logarithmic phase as a therapeutic direction: evaluating pharmacological strategies against cancer progression

      Sushanta Kumar Das, Saptarshi Dutta, Sabitri Pradhan, Rintu Saikia

      • Resumen

      págs. 3708-3729

      

    • Molecular subtyping-guided precision therapy for ESCC: biomarker-driven strategies and clinical translation pathways

      Huifang Lv, Wanying Zhao, Sai Qi Wang, Xiao Bing Chen

      • Resumen

      págs. 3730-3738

      

    • Heterogeneity in primary gastrointestinal DLBCL: from clinical management to molecular mechanisms and treatment strategies

      Xiaohong Liu, Daoming Zhang, Le Xu, Dedong Cao, Ximing Xu

      • Resumen

      págs. 3739-3753

      

  • RESEARCH ARTICLE

    • The early diagnostic value of lung cancer autoantibodies and tumor markers in lung cancer

      Yanyan Hao, Pengfei Wang, Zhiping Zhao, Jiande Cheng

      • Resumen

      págs. 3754-3773

      

    • Exercise inhibits proliferation and induces apoptosis of lung adenocarcinoma cells via the POU2F2-SPOCD1-PI3K/AKT signaling axis

      Shujing Shi, Yumu Leng, Linfei Yang, Buyi Zhu, Haixin Tan, Fengming Wang, Jiaqi Pan, Zhenhua Yang, Wei Gu, Weiwei He

      • Resumen

      págs. 3774-3789

      

    • The prognostic value of methylated ctDNA, soluble PD-L1, and NK-cell activity on the risk of relapse after curative radiotherapy of non-small cell lung cancer

      Thomas Leth Fink, Rikke Fredslund Andersen, Cecilie Mondrup Jacobsen, Line Nederby, Mads Malik Aagaard Jørgensen, Charlotte Kristiansen, Torben Schjødt Hansen, Sara Witting Christensen Wen, Christa Haugaard Nyhus, Rune Slot Thing, Signe Timm, Torben Frøstrup Hansen

      • Resumen

      págs. 3790-3802

      

    • Recommendations for the development of an integrated lung cancer care process: an expert consensus report

      Margarita Majem, Patricia Alonso Fernández, María Pilar Garrido López, Angel Gayete Cara, Florentino Hernando Trancho, José Luis López Guerra, Maria D. Lozano, Bartomeu Massuti Sureda, Luis Paz-Ares Rodríguez, Santiago Ramón y Cajal Agüeras, Vanesa Rodríguez Salés, Luis Miguel Seijo Maceiras, Antoni Sisó Almirall, David Vicente Baz, Laureano Molins López-Rodo

      • Resumen

      págs. 3803-3816

      

    • Stable or not? unraveling the reliability of radiomic features in 4d-computed tomography in early-stage non-small cell lung cancer

      Stefania Volpe, Aurora Gaeta, Maria Giulia Vincini, Mattia Zaffaroni, Federico Mastroleo, Sara Raimondi, Matteo Pepa, Lars Johannes Isaksson, Marta Cremonesi, Davide La Torre, Matthias Guckenberger, Federica Bellerba, Roberto Orecchia, Sara Gandini, Barbara A. Jereczek-Fossa

      • Resumen

      págs. 3817-3827

      

    • First-line versus second-line use of selpercatinib in treatment of RET fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis

      Kai Wang, Wenjie Liu

      • Resumen

      págs. 3828-3838

      

    • Image-based PD-L1 scoring and tumor-infiltrating lymphocytes as predictors for the response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer

      Jianghua Wu, Wei Sun, Xinying Liu, Xin Yang, Luning Mao, Chenglong Wang, Xinting Diao, Dongmei Lin

      • Resumen

      págs. 3839-3849

      

    • Utilization of MRI-based radiomics nomogram for predicting HER2-zero, -low, and -overexpression breast cancer

      Licui Zhang, Qinghong Duan, Ting Zhao, Jian He, Hongyang Li, Zhuoya Ma, Yong Wen, Ying Lei

      • Resumen

      págs. 3850-3861

      

    • Clinical experience and satisfaction in patients with advanced breast cancer participating in the abemaciclib patient support program in Spain: a prospective observational study

      Isabel Blancas López-Barajas, Miriam González de la Peña, María Fernández Abad, Silvia Antolín Novoa, Encarnación Adróver Cebrián, Rodrigo Sánchez Bayona, Esther Zamora Adelantado, Raquel Andrés Conejero, Sonia del Barco Berrón, Manuel Atienza, Alberto Molero, Silvia Díaz Cerezo, Clara Pérez Rambla, F.J. Pérez Sádaba, Luis Manso Sánchez

      • Resumen

      págs. 3862-3871

      

    • Trends in male breast cancer in Spain, 1999–2023: a nationwide analysis of incidence and mortality

      Lucía Cayuela Rodríguez, Victoria Achaval, Gema Flox Benitéz, Julián Librero López, Aurelio Cayuela Domínguez

      • Resumen

      págs. 3872-3879

      

    • Assessing telomerase and Ki-67 protein expression in pre-invasive lesions and invasive cervical neoplasia with correlation to clinico-pathological parameters

      Manal Masoud Musallam Al Awfi, Al Shifaa Ibrahim Said Al Wahaibi, Mohammad Arafa, Hajar Al Badi, Ruqaiya Al Shamsi, Fatma Al Hinai, Samya Al Husaini, Afrah Al Rashdi, Asem Shalaby, Mohamed Mabruk

      • Resumen

      págs. 3880-3896

      

    • PET–CT radiomics and artificial intelligence for predicting lymph node metastasis in cervical cancer: a systematic review and meta-analysis

      Xiaoyu Liu, Junqiang Lei

      • Resumen

      págs. 3897-3906

      

    • A multimodal MRI radiomics model for distinguishing borderline from malignant ovarian epithelial tumors

      Li Liu, Kang Liu, Shuangshuang Zheng, Zhiyuan Gao, Ling Li

      • Resumen

      págs. 3907-3916

      

    • Challenging esophageal surgery: risk factors, outcomes, and a comparative single-center analysis

      Leonardo Duranti, Luca Tavecchio, Luigi Rolli, Piergiorgio Solli

      • Resumen

      págs. 3917-3930

      

    • Prognostic ımpact of the modified Ryan tumor regression score in gastric and GEJ adenocarcinomas treated with neoadjuvant FLOT regimen

      Mehmet Akif Parlar, Burak Bilgin, Bülent Yalçın, Efnan Algın, Öznur Bal, Serhat Sekmek, Furkan Ceylan, Mehmet Ali Nahit Sendur

      • Resumen

      págs. 3931-3940

      

    • Integrative metabolomics and network pharmacology reveal the antifibrotic mechanisms of Gurigumu-13 in a rat model of hepatic fibrosis

      Shuping Tong, Anni Anni, Sudulugeqi Sudulugeqi, Yukun Wang, Xiang Li, Wenbo Du

      • Resumen

      págs. 3941-3958

      

    • Dynamics changes of spleen volume predict survival outcomes in unresectable hepatocellular carcinoma treated with tislelizumab plus lenvatinib

      Zhiyong Xiong, Hao Liang, Moyang Chen, Xi Dang, Xinyuan Huang, Guanghao Zhu, Jizong Lin, Zhicheng Yao, Qingliang Wang, Shilei Xu, Bo Liu

      • Resumen

      págs. 3959-3972

      

    • FAT4 loss promotes tumor growth and ferroptosis resistance in hepatocellular carcinoma via PI3K/AKT pathway activation

      Jing Li, Jialing Sun, Rui Hu, Mengqing Ma, Kongli Fan, Minling Lv, Qi Huang, Wenmin Yang, Yuan Yang, Yan Wang, Xiaozhou Zhou, Xinfeng Sun

      • Resumen

      págs. 3973-3991

      

    • AURKB drives aggressive phenotype and clinicopathological progression in cholangiocarcinoma

      Minglong Wang, Peipei Shang, Yanxi Luo, Meidi Hu

      • Resumen

      págs. 3992-4006